IVF After Breast Cancer

"The idea of waiting while this really aggressive tumor grew inside of me was unsettling." "I feel like my doctor heard my history, saw my test results and has basically written me off." "How do I know if I will regret not having kids??" These are real words from real women — posted on Reddit, whispered in waiting rooms, typed through tears at 2 a.m. If you have breast cancer, survived breast cancer, or carry a BRCA gene mutation, the fear that IVF could feed your cancer is real. And it deserves a real answer.

Here it is: IVF after breast cancer is safe when the right protocol is used. A large systematic review of 4,643 breast cancer patients found that women who underwent ovarian stimulation for fertility preservation had no increased risk of recurrence — and actually showed lower recurrence and mortality rates than women who did not pursue fertility treatment (Su et al., Journal of Clinical Oncology, 2025). The key is a modified IVF protocol that uses letrozole to suppress estrogen during stimulation — keeping your levels 50–70% lower than standard IVF. This is not experimental. It is guideline-recommended care.

Why Standard IVF Raises Concerns for Breast Cancer Patients — and How Letrozole Changes That

In a typical IVF cycle, injectable hormones called gonadotropins stimulate the ovaries to produce multiple eggs. This works well — but it also drives estradiol (a form of estrogen) to levels 10–15 times higher than a natural cycle. For a woman with no cancer history, that temporary spike is not dangerous. But for a woman with estrogen receptor-positive (ER+) breast cancer — which accounts for roughly 75% of breast cancer cases — that spike raises a valid concern. Estrogen can fuel the growth of ER+ tumor cells.

This is exactly why fertility preservation for breast cancer patients requires a different approach. The letrozole protocol solves this problem. Letrozole is an aromatase inhibitor — a drug already used in breast cancer treatment itself — that blocks the conversion of androgens to estrogen. When added to an IVF stimulation cycle, letrozole keeps peak estradiol levels between 338–829 pg/mL, compared to 3,000+ pg/mL in standard IVF (Rodgers et al., Human Reproduction, 2017). The ovaries still respond. Egg yield stays comparable. But the estrogen exposure to breast tissue drops dramatically.

At Rejuvenating Fertility Center (RFC), this is the foundation of our Breast-Safe IVF program. We pair letrozole-based stimulation with GnRH agonist triggers instead of hCG, which further reduces estrogen levels and lowers the risk of ovarian hyperstimulation. For frozen embryo transfers, we use natural ovulation or modified natural cycles — no exogenous estradiol — relying on the body's own progesterone production.

What the Research Says About IVF After Breast Cancer

The fear that fertility treatment could cause breast cancer to return has been studied extensively. The evidence is consistent: letrozole-based ovarian stimulation does not increase recurrence risk.

A prospective controlled study by Kim et al. followed 120 breast cancer patients who underwent the COSTLES protocol (letrozole + gonadotropins) versus 217 controls for an average of 5 years. The hazard ratio for recurrence was 0.77 (95% CI, 0.28–2.13) — meaning no increased risk. Notably, neither BRCA mutation status (P = .57) nor estrogen receptor status affected outcomes (Kim et al., Journal of Clinical Endocrinology and Metabolism, 2016).

A study published in JAMA Oncology compared fertility preservation with and without letrozole in 367 women and found no statistically significant difference in breast cancer-related mortality (aHR 0.45 vs. 0.59; P = .69) or relapse (aHR 0.98 vs. 0.72; P = .54), with consistent safety results beyond 5 years of follow-up (Marklund et al., JAMA Oncology, 2022).

Even at the molecular level, the data is reassuring. The BROVALE study measured circulating tumor DNA (ctDNA) before and after letrozole-based stimulation in 29 early breast cancer patients. Among 15 patients with detectable mutations, 93% (14 out of 15) showed no increase in ctDNA levels after stimulation (Rothé et al., Frontiers in Oncology, 2021).

Study	Patients	Protocol	Recurrence Finding	Follow-up
Su et al., JCO, 2025 (15-study review)	4,643	COS with letrozole	RR 0.58 (reduced risk)	Varies (median <5 yr)
Kim et al., JCEM, 2016	337	COSTLES (letrozole + gonadotropins)	HR 0.77 (no increased risk)	5 years
Marklund et al., JAMA Oncology, 2022	367	COS ± letrozole	No significant difference in relapse	5+ years
Rothé et al., Frontiers in Oncology, 2021	29	Letrozole-COS with ctDNA monitoring	93% showed no ctDNA increase	Short-term molecular

What a Breast-Safe IVF Cycle Actually Looks Like — The Part Nobody Explains

This is the gap in almost every article ranking for "can you do IVF with breast cancer." They tell you IVF is safe. They cite the same studies. But they never walk you through what the modified cycle actually feels like as a patient — how it differs from standard IVF day by day, and why those differences matter for your breast tissue.

Days 1–2: You start letrozole (5 mg daily by mouth) on day 2 or 3 of your menstrual cycle. No injections yet. Letrozole begins blocking estrogen production immediately.

Days 3–4: Low-dose gonadotropin injections are added — typically 150–300 IU of recombinant FSH. This is often lower than a standard IVF dose. Letrozole continues daily alongside the injections.

Days 5–10: Monitoring via blood draws and transvaginal ultrasound every 2–3 days, exactly like standard IVF. Your doctor watches follicle growth and estradiol levels. Here is the difference you can see in your lab results: where a standard IVF patient might have estradiol of 2,000–4,000 pg/mL by this point, yours stays below 800 pg/mL. Your ovaries are still responding. Your breasts are not being flooded with estrogen.

Trigger day: When follicles are mature (typically around day 10–12), you receive a GnRH agonist trigger instead of the traditional hCG trigger. This causes a shorter, smaller hormone surge — another layer of protection.

Egg retrieval: 34–36 hours after trigger, eggs are retrieved via the same ultrasound-guided procedure used in all IVF. After retrieval, letrozole continues for about one week until estradiol falls below 50 pg/mL.

After retrieval: Eggs or embryos are frozen. If you are freezing before chemotherapy, the entire process takes approximately 2–3 weeks from cycle start — a timeline the ASCO guidelines recommend factoring into treatment planning. At RFC, we coordinate directly with your oncologist to avoid any delay in cancer treatment.

For patients who return after cancer treatment for a frozen embryo transfer, RFC uses natural ovulation or modified natural FET cycles — no estrogen pills, no estrogen patches. Your body's own cycle prepares the lining. Vaginal progesterone supplementation may be provided if needed, but exogenous estradiol is avoided entirely.

What To Do If You Want to Preserve Fertility Before or After Breast Cancer Treatment

Step 1: Get your baseline bloodwork before anything else. Request AMH (anti-Müllerian hormone), FSH, estradiol, and an antral follicle count via ultrasound. These tell your reproductive endocrinologist how many eggs you have to work with and how urgently you need to act. BRCA1 carriers in particular may have diminished ovarian reserve and earlier menopause (Chen et al., Fertility and Sterility, 2019), making early referral — ideally in your late 20s to early 30s — especially important.

Step 2: Ask your reproductive endocrinologist these specific questions:

• Do you use a letrozole-based stimulation protocol for breast cancer patients?

• Will you use a GnRH agonist trigger instead of hCG?

• For embryo transfer, do you offer natural or modified natural FET cycles without exogenous estradiol?

• Will you coordinate timing directly with my oncologist?

• Do you offer preimplantation genetic testing (PGT) to screen embryos for BRCA mutations?

If the answer to any of these is "no" or "we don't do that," seek a second opinion. Not every fertility clinic has an oncofertility-specific program. The NCCN Breast Cancer Guidelines recommend that all premenopausal patients be informed about fertility impact and referred to specialists before chemotherapy or endocrine therapy.

Step 3: Know your realistic timeline. Egg or embryo freezing takes about 2–3 weeks from the start of your menstrual cycle. Most oncologists can accommodate this window before chemotherapy begins. If you are already post-treatment and your periods have not returned, your RE can still assess your ovarian reserve and discuss next steps.

Step 4: Understand costs. Some states mandate insurance coverage for fertility preservation when a medical treatment threatens fertility. New York, Connecticut, and several other states have oncofertility coverage laws. Ask your clinic's financial coordinator about your specific plan before assuming you will pay out of pocket.

Frequently Asked Questions

Can IVF make breast cancer come back?

The largest body of evidence says no. A systematic review of over 4,600 breast cancer patients found that those who underwent ovarian stimulation for fertility preservation actually had lower recurrence rates than those who did not (Su et al., Journal of Clinical Oncology, 2025). This held true even for women with ER-positive tumors when a letrozole protocol was used. No study has shown increased recurrence with letrozole-based stimulation.

Is it safe to do IVF if I carry a BRCA1 or BRCA2 mutation?

Yes. A 2024 ESMO study — the first of its kind for BRCA carriers specifically — analyzed nearly 5,000 women with BRCA1/2 mutations diagnosed with breast cancer at age 40 or younger. Women who conceived using assisted reproductive technology had no increased risk of recurrence compared to those who conceived naturally. The Society of Gynecologic Oncology and ASRM state that fertility medications do not appear to increase breast cancer risk in BRCA carriers, and recommend letrozole-gonadotropin protocols to minimize estradiol (Chen et al., Fertility and Sterility, 2019).

How long do I have to wait after chemo to try IVF?

This depends on your specific treatment plan. The POSITIVE trial showed that younger women with early-stage, hormone receptor-positive breast cancer could safely pause endocrine therapy to attempt pregnancy, with 36% using assisted reproductive technology including IVF. Your oncologist and reproductive endocrinologist should make this decision together based on your cancer stage, treatment regimen, and time since last treatment. Most experts recommend waiting at least 6–12 months after chemotherapy ends.

My doctor never mentioned fertility preservation — did I miss my window?

You are not alone. Research shows that many oncologists do not present all fertility options to their patients — and patients often feel they must self-advocate to have their fertility concerns heard. As one woman posted: "Why do I have to be the one to take initiative?" If you have completed treatment, your ovarian reserve may still support egg retrieval. If it has been significantly depleted, options like donor eggs or embryo adoption remain available. The window is wider than many patients are told.

You Deserve a Team That Understands Both Sides

Breast cancer does not have to mean giving up on parenthood. But you need a fertility team that speaks both languages — oncology and reproductive medicine — and builds your protocol around your safety. That is exactly what the Breast-Safe IVF program at Rejuvenating Fertility Center was designed to do. If you are ready to talk through your options with a team that coordinates directly with your oncologist, schedule a consultation with RFC.